
Opinion|Videos|February 17, 2025
The Role of Private Label Agreements in Enhancing Access to Biosimilars
Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the role of private label agreements and how can they enhance access to biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
2
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
New TROP2-Targeted ADC Shows Promise in TNBC: Erika Hamilton, MD
5
















































